DRMA
NASDAQ
US
Dermata Therapeutics, Inc. - Common Stock
$1.29
▲ +$0.09
(+7.50%)
Vol 157K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$2.4M
ROE
-192.0%
D/E
0.00
Beta
0.55
52W
$2–$24
Wall Street Consensus
7 analysts · Apr 20262
Strong Buy
4
Buy
1
Hold
0
Sell
0
Strong Sell
85.7%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 60.0%
Next Report
May 12, 2026
EPS Estimate: $-0.54
| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Mar 2026 | $-0.54 | — | — |
| Dec 2025 | $-1.57 | $-1.52 | +$0.05 |
| Sep 2025 | $-1.62 | $-1.65 | $-0.03 |
| Jun 2025 | $-2.96 | $-1.66 | +$1.30 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$3.2M | -$3.2M | -$2.3M | -$1.7M | -$1.7M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -215.0% | -215.0% | -215.0% | -215.0% | -215.0% | -192.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 6.47 | 6.47 | 6.47 | 6.47 | 6.47 | 4.56 |
Key Ratios
ROA (TTM)
-140.2%
P/B
1.8
EPS (TTM)
$-28.37
CF/Share
$-1.17
52W High
$23.70
52W Low
$1.80
$1.80
52-Week Range
$23.70
Financial Health
Free Cash Flow
-$1.8M
Cash
$4.7M
As of Sep 30, 2025
How does DRMA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
DRMA valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
1.8
▼
28%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
DRMA profitability vs Biotechnology peers
ROE
-192.0%
▼
185%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-140.2%
▼
200%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
DRMA financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
4.6
▲
3%
above
peers
(4.4)
vs Peers
vs Industry
In line
Beta
0.6
▼
43%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
DRMA fundamentals radar
DRMA
Peer median
Industry
DRMA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
DRMA vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
BEDOYA-TORO MUNERA MARIA E
Officer · Feb 17
1000 shs
Last 90 days
Top Holders
Top 5: 0.91%Clear Street Group Inc.
0.60%
$20K
Bank of America Corporation
0.12%
$4K
Barclays Plc
0.08%
$3K
Tower Research Capital LLC …
0.07%
$2K
UBS Group AG
0.04%
$1K
As of Dec 31, 2025
Latest News
No related news yet